tagitanlimab   Click here for help

GtoPdb Ligand ID: 13795

Synonyms: A-167 | Cotelet® | HBM-9167 | KL-A167 | KLA167
Approved drug Immunopharmacology Ligand
tagitanlimab is an approved drug
Compound class: Antibody
Comment: Tagitanlimab (KL-A167) is a humanized anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody [1]. It is designed to block the inhibitory PD-1/PD-L1 immune checkpoint and restore anti-tumour immunity.
No information available.
Summary of Clinical Use Click here for help
Tagitanlimab (KL-A167) is a clinical candidate therapeutic for the treament of advanced solid tumours and lymphoma. It is being tested as a monotherapy and in combination with other anti-tumour agents. The Chinese drug regulator (NMPA) approved tagitanlimab (Cotelet®)- combined with cisplatin and gemcitabine- in late 2024, to treat recurrent/metastatic nasopharyngeal cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer Phase 2 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. Phase 2 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT05294172 KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Phase 3 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT03580564 An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma Phase 2 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT03848286 KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Phase 2 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. 1